sign in sign up
<<
Home , Drug interaction, Raloxifene

Mental Illness 2019; volume 11:8115

Interactions between of and cancer treatment-mediated , sleep aids and structural and functional dysfunction, Correspondence: Robert G. Bota, Department which affects the hippocampus and decreas - of Psychiatry, University of California Irvine, selected cancer therapy es hippocampal neurogenesis. 1-4 As many 101 City Drive as 35% of cancer patients suffer from Orange, CA, USA. Jody Jacobson Wedret, 1 Thanh G. Tu, 2 depression and over 10% have major Tel.: +1.229.815.0219 - Fax: +1.714.456.2056. E-mail: [email protected] Doru Paul, 3 Camille Rousseau, 4 depressive disorder. 5,6 Similarly, insomnia 1 1 affects up to 50% of patients with cancer. 7 Augustin Bonta, Robert G. Bota Key words: depression, insomnia, cancer Therefore, pharmacological options are 1University of California Irvine, Orange, patients, drugs . often employed to address insomnia and/or CA, USA; 2University of California San depression in this patient population. Contributions: the authors contributed equally. Francisco, San Francisco, CA, USA; With all disease states and especially 3 Cornell University, Ithaca, NY, USA; with cancer, close attention to drug-drug Conflict of interest: the authors declare no 4 University of Bordeaux, France and the potential impact on the potential conflict of interest. efficacy of therapy is paramount. One area of particular interest due to the lack of well- Funding: none. Abstract done clinical trials is drug-drug interaction(s) between antidepressants and Received for publication: 18 March 2019. Depression and insomnia are very sig - cancer treatment. Without reliable clinical Accepted for publication: 18 March 2019. nificant pathologies in cancer patients as trials to vet the potential drug-drug This work is licensed under a Creative they contribute to the patient’s overall cure interactions, we are left with theoretical and quality of life. Moreover, untreated Commons Attribution-NonCommercial 4.0 evidence and educated deductive reasoning. International License (CC BY-NC 4.0). depression and ongoing insomnia are asso - With that said, the pharmacological ciated with decreased immune responses treatment of depression in patients with ©Copyright J.J. Wedret, et al., 2019 and lower survival rates. With all disease cancer presents unique challenges caused Licensee PAGEPress, Italy states and especially with cancer, close by drug-drug interactions between Mental Illness 2019; 11:8115 attention to drug-drug interactions and the antidepressants and cancer doi:10.4081/mi.2019.8115 potential impact on the efficacy of therapy pharmacotherapy, which may lower the is paramount. One area of particular interest effectiveness of cancer treatment. 1-4 Despite due to the lack of well-done clinical trials is the impact of depression in patients with level of active metabolites or decreased level drug-drug interaction(s) between cancer, studies looking at the efficacy of of active parent drugs. Secondly, considera - antidepressants and cancer treatment. medications in this tion for the clinical significance of drug inter - of a certain drug allows population are very few and of low quality. actions to inform our clinical decisions is a for prediction of certain drug interactions On the other hand, the pharmacological must. In regards to , based on chemical properties of the agents options available for treatment of insomnia changes in drug levels secondarily to involved. If the agents depend on their pose less of a challenge in terms of drug- inhibition or induction may metabolites for activity, active drug level drug interactions for patients currently on not be as clinically significant as hypotheti - will be decreased through this inhi - cancer pharmacotherapy. cally predicted depending on the therapeutic bition. In this paper, we looked at the indexes of the agents involved. cytochrome-P450 drug interactions between antidepressants and sleep aids with Methodology Selective Modulators (SERM). Newer SERM are We approached the topic of drug Selective less influenced by interactions with interactions in setting of depression and/or Modulators (SERMs): , medications used to treat depression. insomnia and from two raloxifene, different perspectives. First, the pharmacoki - However, tamoxifen could be Selective estrogen receptor modulators severely altered by several antidepressants. netics of a certain drug allows for prediction of certain drug interactions based on chemi - (SERMs), including tamoxifen, raloxifene This has direct consequences as patients on and toremifene, are drugs commonly used in tamoxifen and antidepressant can have cal properties of the agents involved. In gen - eral, inhibitors of cytochrome P450 breast cancer treatment. Particularly, tamox - double the risk of relapse to cancer in two ifen, a cost effective SERM that is commonly years. We discussed those interactions and enzyme(s) will reduce metabolism of enzyme substrates. If the agents depend on their used, is a that is metabolized through made recommendations for clinical use. metabolites for activity, active drug level will various cytochrome P450 , specifi - be decreased through this enzyme inhibition. cally CYP3A4, CYP3A5 and CYP2D6, to For instance, tamoxifen is a prodrug, a bio - give three active metabolites. 7 Therefore, logically inactive compound that requires drugs that inhibit these enzymes, especially Introduction CYP2D6 enzymatic activation to yield the CYP2D6, may decrease tamoxifen active Depression and insomnia are very sig - , . Therefore, metabolite level, potentially diminishing nificant pathologies in cancer patients as enzymatic inhibition of CYP2D6 will tamoxifen’s anti-cancer effect. Importantly, they contribute to the patient’s overall cure decrease metabolism of parent drug tamox - this drug-drug interaction through and quality of life. Moreover, untreated ifen and thus decrease level of active metabo - cytochrome P450 metabolic pathways may depression and ongoing insomnia are asso - lite endoxifen. On the other hand, inducers of increase the recurrence of cancer in patients ciated with decreased immune responses cytochrome P450 enzyme(s) will increase concomitantly taking tamoxifen and a and lower survival rates. Depression in can - metabolism and of enzyme sub - CYP2D6 inhibitor. 8 cer patients is the phenotypic manifestation strates, which will result in either increased Conversely, SERMs that are not reliant

[page 36 ] [Mental Illness 2019; 11:8115] Review on CYP2D6 for metabolism pose a less com - drug interaction are largely dependent on the cokinetic studies of various antidepressants plicated challenge in regards to drug-drug therapeutic indexes of drugs involved. and their potential impact on the metabolism interactions relative to tamoxifen. Raloxifene of SERMs, especially tamoxifen, the follow - undergoes while toremifene ing conclusions were drawn. As shown in utilizes CYP3A4 for its metabolism. Figure 1, paroxetine, and bupropion Therefore, the challenge in using raloxifene Pharmacological treatment for are amongst the strongest CYP2D6 inhibitors or toremifene concomitantly with CYP2D6 depression of the antidepressants. 1-6,8-17 Despite the con - inhibitors such as certain antidepressants is Pharmacological interventions for troversial evidence available regarding the unparalleled to tamoxifen. The differences in depression include several categories of med - clinical significance of these strong inhibitory metabolism and the pathways employed by ications, including selective serotonin reup - activity on tamoxifen’s anticancer effect, it is each medication partially explain the varia - take inhibitors (SSRI), serotonin norepineph - premature to dismiss these interactions given tions in drug-drug interactions between rine reuptakes inhibitors (SNRI), and tricyclic the lack of strong evidence proving unchanged SERMs and antidepressants. 9,10 Overall, the antidepressants (TCA). mortality rate with paroxetine, fluoxetine and clinical pharmacodynamic effects of each Upon review of clinical trials and pharma - bupropion. On the other hand, , 11

Figure 1. Cytochrome-P450 Drug Interactions between Antidepressants and Selective Estrogen Receptor Modulators (serms). Classification of antidepressants’ cytochrome P450 inhibition based on available pharmacokinetic data. 1-6,8-17 Green ( ): No inhibi - tion; Yellow ( ): Mild inhibition; Orange ( ): Moderate inhibition; Red ( ): Strong inhibition. Recommendation based on clinical relevance of cytochrome P450 interactions. aConsider therapy modification: Evidence available to support clinically significant decrease in efficacy of selected breast cancer pharmacotherapy as measured by all-cause mortality and/or breast cancer recurrence. bMonitor ther - apy: Lack of evidence available or available evidence suggests clinically insignificant decrease in efficacy of selected breast cancer phar - macotherapy as measured by all-cause mortality and/or breast cancer recurrence. Cno action required: No known or exp⟷ected clinically significant int↓eraction. ↓↓ ↓↓↓

[Mental Illness 2019; 11:8115] [page 37 ] Review

death. Harv Ment Health Lett 2010;26:6- 7. 9. Kim J, Peraire C, Sola J, et al. Drug inter - action potential of toremifene and N- desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica 2011;41:851-62. 10. Fareston. Package insert: GTx, INc, TN, 2011. 11. Chubak J, Bowles EJ, Yu O, et al. Breast cancer recurrence in relation to antide - pressant use. Cancer Causes Control 2016;27:125-36. 12. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009;70:1688-97. 13. Hemeryck A, Belpaire FM. Selective Figure 2. Cytochrome-P450 Drug Interactions between Selected Sleep Aids and Selective serotonin reuptake inhibitors and Estrogen Receptor Modulators (SERMs). Classification of sleep aids’ cytochrome P450 cytochrome P-450 mediated drug-drug interactions based on available pharmacokinetic data. Green ( ): No interaction. interactions: an update. Curr Drug Metab Recommendation based on clinical relevance of cytochrome P450 interactions. cNo action required, No known or expected clinically significant interaction. 2002;3:13-37. 14. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamox - ⟷ ifen metabolism during adjuvant breast 12-15,18,19 and escitalo - cancer treatment. J Natl Cancer Inst pram 12,13,15,18,19 are metabolized through vari - References 2005;97:30-9. ous cytochrome P450 enzymes but are not an 1. Gust J, Hay KA, Hanafi LA, et al. 15. English BA, Dortch M, Ereshefsky L, et inhibitor of these enzymes; therefore, they are Endothelial Activation and Blood-Brain al. Clinically significant psychotropic reasonable candidates for treatment of depres - Barrier Disruption in Neurotoxicity after drug-drug interactions in the primary care sion or mood disorders in the setting of breast Adoptive Immunotherapy with CD19 setting. Curr Psychiatry Rep cancer treatment with tamoxifen, a CYP2D6 CAR-T Cells. Cancer Discov 2012;14:376-90. . Similarly, 12,14,15 is a 2017;7:1404-19. 16. Information: P. Temazepam. In: good option albeit very minor inhibitory activ - 2. Vitali M, Ripamonti CI, Roila F, et al. Mallinckrodt Inc SL, MO, ed., 2002. ity on CYP2D6 relative to other SSRIs and Cognitive impairment and chemothera - 17. Moltke L. Zolpidem metabolism : SNRIs. Given a variety of safe options based py: a brief overview. Crit Rev Oncol responsible cytochromes, chemical on the available clinical evidence for treatment Hematol 2017;118:7-14. inhibitors, and in vivo correlations. Br J of depression and concomitant tamoxifen, take 3. Ren X, St Clair DK, Butterfield DA. Clin Pharmacol 1999;48:89-97. caution when prescribing antidepressants with Dysregulation of cytokine mediated 18. Donneyong MM, Bykov K, Bosco-Levy strong CYP2D6 inhibitory activity like parox - chemotherapy induced cognitive impair - P, et al. Risk of mortality with concomi - etine, fluoxetine and bupropion to patients cur - ment. Pharmacol Res 2017;117: 267-73. tant use of tamoxifen and selective sero - rently taking tamoxifen. 4. Wardill HR, Mander KA, Van Sebille tonin reuptake inhibitors: multi-database YZ, et al. Cytokine-mediated blood brain cohort study. BMJ 2016;354:i5014. barrier disruption as a conduit for can - 19. Lash TL, Cronin-Fenton D, Ahern TP, et cer/chemotherapy-associated neurotoxic - al. Breast cancer recurrence risk related Pharmacological treatment of ity and cognitive dysfunction. Int J to concurrent use of SSRI antidepressants insomnia Cancer 2016;139:2635-45. and tamoxifen. Acta Oncol 2010;49:305- 5. Zainal NZ, Nik-Jaafar NR, Baharudin A, Pharmacological interventions for insom - 12. et al. Prevalence of depression in breast nia also include several categories of medica - 20. Information P. Restoril, temazepam. cancer survivors: a systematic review of tions such as , hypnotics and Mallinckrodt Inc, St Louis, MO 2002. observational studies. Asian Pac J Cancer others. Although there are variations in the 21. Information P. . In: Pharmacia Prev 2013;14:2649-56. metabolic pathway of each SERM as stated & Upjohn Company K, MI, ed., 2003. 6. Ng CG, Boks MP, Zainal NZ, et al. The above, available pharmacokinetic and phar - 22. Information P. . In: Takeda prevalence and pharmacotherapy of macodynamic data show no clinically rele - Pharmaceuticals America I, Lincolnshire, depression in cancer patients. J Affect vant interactions between the selected sleep ed., 2005. Disord 2011;131:1-7. aids and SERMs. Figure 2 details the relative 23. Brielmaier BD. Eszopiclone (Lunesta): a 7. Appiani F, Carroll BT, Munoz C, et al. metabolic pathway employed by each SERM new nonbenzodiazepine hypnotic agent. Tamoxifen-SSRIs interaction: clinical as well as the level of drug-drug interactions Proc (Bayl Univ Med Cent) 2006;19:54- manifestations of inhibition and lack of with various sleep aids commonly used in 9. inhibition of CYP2D6. Ann Clin practice. 16,17,20-24 24. Whirl-Carrillo M, McDonagh EM, Psychiatry 2011;23:152-3. Hebert JM, et al. Pharmacogenomics 8. [No authors listed]. Antidepressants and knowledge for personalized medicine. tamoxifen. Drug interactions may Clin Pharmacol Therapeut 2012;92: increase risk of cancer recurrence or 414-17. [page 38 ] [Mental Illness 2019; 11:8115]